Finally, NCT06259123 is a single-center phase II trial (Austria), recruiting 10 oligometastatic PCa planned for RPE diagnosed by [68Ga]Ga-PSMA-11 PET (M1a, and/or M1b with ≤ 5 bone metastases, and/or M1c with ≤ 3 lung metastases). This evidence concerns the gene FOLH1 and posterior cortical atrophy.